Global liquid biopsies market is anticipated to reach 5,958.3 million by 2030, according to a new report by Grand View Research, Inc. As these less invasive biopsies are able to address a number of significant challenges associated with conventional biopsies such as, high level of invasiveness, incompleteness of cancer information that is acquired, associated post-biopsy serious medical complications, and subsequent cost inclusions. A growing need for more advanced, efficient and accurate method which provides a holistic view of the tumor and metastasis is the prime factor fueling rapid development of liquid biopsies.
The market has gained considerable traction in the past couple of years. A number of clinical research projects related to circulating tumor cells, and cell-free tumor DNA have been initiated in the latter half of the past decade. As a result, there are a number of ongoing clinical trials that are due to be completed between post 2017-18. It is expected that upon successful completion, commercialization of these assays and tests will provide the market a significant boost in potential addressable target revenue and fuel growth through to 2030.
View summary of this report @ http://www.grandviewresearch.com/industry-analysis/liquid-biopsy-market
Further key findings from the report suggest:
·
In terms of applications, therapy selection of
metastatic cancers is the key area of liquid biopsy usage as these provide
significant insights into the unique genetic information encoded in CTCs and
ctDNAs. Furthermore, with the addition of more research data reinforcing the
usage of liquid biopsies over the coming years, it is expected that their
application for molecular monitoring of diseases will also be a lucrative
source of revenue through to 2030
·
Key biomarkers that any liquid biopsy targets
include circulating tumor cells, circulating tumor DNA and exosomes that are
macrovesicles containing tumor RNA, or tumor protein freely circulating in the
patient’s bloodstream. Assays for ctDNA are expected to account for the largest
share of revenue through to 2030 owing to the currently present assays and
expected number of products that are to be commercialized over the coming
decade.
·
Development of parallel multi-gene analysis
using next generation sequencing technology is the underlying factor that has
enabled oncologists to more efficiently sequence ctDNA and gain insights
related to cancer metastasis and the related mechanism. This understanding
provides a patient-centric systemic view of cancer and aids in its long term
monitoring.
·
North America, specifically the U.S. accounts
for the largest share of revenue for the development of liquid biopsy market.
The region was observed to account for around 50% of the global potential in
2015 owing to the high number clinical development projects underway for the
commercialization of CTC and ctDNA assays till 2020. Furthermore, throughout
the forecast period, U.S. is expected to dominate revenue generation owing to
the dynamic nature & being the region of prime activity, research and
development with respect to liquid biopsy and next generation sequencing
technology.
·
Although, post successful commercialization
through to 2030, Asia Pacific is expected to be a lucrative region for
development as it is expected to be characterized by the presence of a large
patient population base, developing healthcare framework and growth in
integration of more advanced healthcare practices.
·
The market is in its developing phase and is
characterized by the presence of a number of relatively smaller entities
involved in innovation and new product development. Companies such as Biocept,
Adaptive Biotechnologies, NeoGenomics Laboratories, Guardant Health, Qiagen,
Personal Genome Diagnostics, Cynvenio, RainDance Technologies, and Trovagene
are operating in the space and have a number of commercialized assays in their
portfolios for liquid biopsy.
·
Furthermore, as this space has a high lucrative
potential, and is considerably influenced by the developments in NGS
technology, there are a number of major players that have ongoing
investigational & observational clinical trials and are due to be completed
by 2017 to 2019. Collectively, over 30 clinical trials are currently registered
as active by companies including Illumina, Foundation Medicine, Natera Inc.,
Roche, Sequenom, LabCorp, Epic Sciences, and Pathway Genomics in the U.S.
alone. Anticipated successful commercialization of these products is expected
to fuel growth over the forecast period.
Browse
more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented
the liquid biopsy market on the basis of application, sample type, biomarker,
technology, and region:
Global Liquid Biopsy Outlook, by
Application (Revenue, USD Million, 2013 - 2030)
- Therapy Selection for Metastatic Breast Cancer (MBS)
- Therapy Selection for Other Metastatic Cancer
- Molecular Health Monitoring
Global Liquid Biopsy, by Sample Type
(Revenue, USD Million, 2013 - 2030)
- Blood Sample based
- Urine Sample based
- Other Bio Fluids (Tissue fluids and Saliva) based
Global Liquid Biopsy Outlook, by
Biomarker, (Revenue, USD Million, 2013 - 2030)
- Circulating Tumor Cells (CTC)
- Circulating Tumor DNA (ctDNA)
- Exosomes
Global Liquid Biopsy Outlook, by
Biomarker, (Revenue, USD Million, 2013 - 2030)
- Multi - gene - parallel Analysis (NGS)
- Single Gene Analysis (PCR Microarrays)
Global Liquid Biopsy Market,
Regional Outlook (Revenue, USD Million, 2013 - 2030)
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- Asia Pacific
- China
- Japan
- Latin America
- Brazil
- MEA
- South Africa
No comments:
Post a Comment